Drug intelligence / Profile preview

IMT-0752

Development stage: Preclinical
Lead developer: ImunoTera

Overview

IMT-0752 is a preclinical-stage immunotherapy candidate being developed by the Brazilian biotechnology company ImunoTera for the treatment of HER2-positive (HER2+) breast cancer. The drug is designed to target the Human Epidermal Growth Factor Receptor 2 (HER2), a well-validated oncogenic driver that is overexpressed in approximately 15-20% of breast cancer cases. While ImunoTera's core technology platforms typically involve therapeutic vaccines such as recombinant proteins or DNA vaccines, the specific modality for IMT-0752 is currently listed as "to be defined" (TBD) in the company's pipeline. The program aims to leverage the immune system to specifically recognize and eliminate HER2-expressing tumor cells, potentially offering a new therapeutic approach for patients with HER2-driven malignancies.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on IMT-0752.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMT-0752.

Explore the full profile